Feature | May 14, 2014

National Lipid Assn. Releases Draft Recommendations for Patient-Centered Treatment of Dyslipidemia

Health care providers invited to review and comment on recommendations before final publication

May 14, 2014 — The National Lipid Assn. (NLA) released a draft summary that highlights key aspects of care that provide a thorough supplement and direction for clinicians treating patients with dyslipidemia.

The document was created by an expert panel comprised of NLA members who are leaders in the field of clinical lipidology. The panel’s goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American Heart Assn./American College of Cardiology and those also released in the international community.

“We wanted to make sure that any clinician following guidelines realizes that they are just that: guidelines to be used in a broad sense of the word,” said Matthew K. Ito, doctor of pharmacy and president of the NLA. “But we realize that individual patients bring a set of problems that are relatively uncommon when considered as a package. Considering only risk factors that are suitable to community-based analysis does not get the job done. Generalizations based on such data can often lead to an unsatisfactory approach to the individual patient.”

As such, the NLA recommendations make it clear that clinicians should assess patient risk and be able then to identify a treatment regime that gets the patient to well established goals.

“As lipidologists, the NLA wants to assist all clinicians to best manage their patients within the context of 'real world' medicine,” said Ito. “We believe these recommendations do that; they are both clinically practical and scientifically based.”

While the NLA encourages adoption and use of these recommendations, it recognizes that clinical judgment and evolving evidence constantly need to be incorporated to fortify clinician approaches to patient care.

Highlights of the recommendations for patient-centered treatment of dyslipidemia include:

Assessing Risk

  • Risk identification is the first crucial step to arrive at appropriate decisions by the health care provider and the patient to initiate healthy lifestyle changes and, potentially, drug therapy. The highest risk patients for future cardiovascular disease (CVD) events will always be those with established atherosclerotic cardiovascular disease (ASCVD).
  • In primary prevention situations, the presence of three or more major risk factors, familial hypercholesterolemia (FH) and simultaneously occurring high-risk disease states (such as diabetes and chronic kidney disease) are to be considered high-risk status.
  • Risk calculators can be confusing for many clinicians but can be beneficial when addressing patients that fall in the moderate risk group. The Framingham Risk Score 10-year hard coronary heart disease (CHD) endpoints is the preferred one for clinical decisions. Lifetime risk can also be used for patients under 50 years old.

Measures and Goals

  • Non-HDL-C and LDL-C are the clinical measures of atherogenic lipoprotein contribution to ASCVD risk, and these parameters should be obtained in the baseline assessment and as targets of treatment.
  • Clinicians should always steer therapy toward meeting goals, including lifestyle choices like diet and exercise, and include therapeutics when necessary to achieve the stated goals.

The NLA is seeking input and comments from NLA members, stakeholder organizations and other related medical societies as well any other individual or group who cares for patients with dyslipidemias and other related disorders.

Comments on this document can be made until May 31, 2014 at www.lipid.org/publiccomments.

After the NLA has received comments from all entities, the expert panel will reconvene and consider every comment submitted regarding these recommendations. The expert panel will then review and adjudicates the comments, publishing a final paper in the September/October issue of the Journal of Clinical Lipidology.

For more information: www.lipid.org

Related Content

An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| May 16, 2017
May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 a
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial
News | Stroke| May 12, 2017
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial...
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Ablation procedure, EP lab, Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation
Feature | Atrial Fibrillation| March 29, 2017
March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
PCI, drugs, medication, fully blocked arteries, chronic total occlusion, ACC.17, clinical study
News | Chronic Total Occlusion (CTO)| March 29, 2017 | Dave Fornell
March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init